MARLBOROUGH, Mass.,
Nov. 4, 2016 /PRNewswire/ -- Boston
Scientific Corporation (NYSE: BSX) today announced that its wholly
owned merger subsidiary, Falcon Merger Corp., has extended its
previously announced tender offer for all shares of EndoChoice
Holdings, Inc. (GI) at a price of $8.00 per share net to the holder in cash.
Boston Scientific has extended the expiration of the Offer until
one minute following 11:59 p.m.,
New York City time, on
November 21, 2016, unless further
extended in accordance with the Merger Agreement. The Offer, which
was previously scheduled to expire one minute following
11:59 p.m., New York City
time, on November 4, 2016, was
extended to allow additional time for the satisfaction of the
conditions of the Offer set forth in the Merger Agreement (as
defined in the Offer to Purchase). The Depositary has advised
Boston Scientific that, as of the close of business, New York City time on November 3, 2016, approximately 17,332,100 Shares
have been validly tendered and not properly withdrawn pursuant to
the Offer, representing approximately 66.5% of the Shares
outstanding, determined on a fully diluted basis, as defined in the
Merger Agreement.
About Boston Scientific
Boston Scientific transforms
lives through innovative medical solutions that improve the health
of patients around the world. As a global medical technology leader
for more than 30 years, we advance science for life by providing a
broad range of high performance solutions that address unmet
patient needs and reduce the cost of healthcare. For more
information, visit www.bostonscientific.com and connect
on Twitter and Facebook.
About EndoChoice
Based near Atlanta, Georgia, EndoChoice (NYSE: GI) is a
medical technology company focused on the manufacturing and
commercialization of platform technologies including endoscopic
imaging systems, devices and infection control products and
pathology services for specialists treating a wide range of
gastrointestinal conditions, including colon cancer. EndoChoice
serves more than 2,500 customers in the
United States and works with distribution partners in 30
countries. EndoChoice was founded in 2008 and has rapidly developed
a broad and innovative product portfolio. EndoChoice and Full
Spectrum Endoscopy (Fuse®) are registered trademarks of EndoChoice
Holdings, Inc.
NOTICE TO INVESTORS ABOUT THE OFFER:
This announcement is neither an offer to purchase nor a
solicitation of an offer to sell securities. The solicitation and
the offer to buy shares of EndoChoice's common stock is being made
pursuant to an Offer to Purchase and related tender offer materials
that Falcon Merger Corp. has filed with the Securities and Exchange
Commission (SEC) on October 7, 2016.
Falcon Merger Corp. has filed a Tender Offer Statement on Schedule
TO with the SEC on October 7, 2016,
and filed Amendment No. 1 to the Schedule TO on October 27, 2016 and EndoChoice has filed a
Solicitation/Recommendation Statement on Schedule 14D 9 with the
SEC on October 7, 2016, as amended
with Amendment No. 1 on October 11,
2016 and Amendment No. 2 on October
27, 2016 related to the tender offer. The Tender Offer
Statement (including an Offer to Purchase, a related Letter of
Transmittal and other tender offer documents) and the
Solicitation/Recommendation Statement will contain important
information that should be read carefully before any decision is
made with respect to the tender offer. Those materials will be made
available to EndoChoice's shareholders at no expense to them by
D.F. King & Co., Inc. by
contacting D.F. King & Co. at
(212) 269-5550 (collect) or (800) 487-4870 (toll free). In
addition, all of those materials (and all other offer documents
filed with the SEC) are available at no charge on the SEC's website
at www.sec.gov.
CONTACT:
Media:
Catherine Brady
508-683-4797
Media Relations
Boston Scientific Corporation
Catherine.Brady@bsci.com
Investors:
Susie Lisa, CFA
508-683-5565 (office)
Investor Relations
Boston Scientific Corporation
investor_relations@bsci.com
EndoChoice Contact:
David Gill, President & Chief
Financial Officer
david.gill@endochoice.com
678-585-1040
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/boston-scientific-announces-extension-of-the-cash-tender-offer-for-all-shares-of-endochoice-300357452.html
SOURCE Boston Scientific Corporation